Login to Your Account

Clinic Roundup

Friday, October 4, 2013
• Atlab Pharma SAS, of Nantes, France, presented data at the European Cancer Congress in Amsterdam, from a Phase I trial with expansion cohorts involving 41 patients treated with fractionated doses of ATL101 for prostate cancer, reporting significant antitumor activity with a trend in dose-dependent effect on overall survival associated to a good tolerance and manageable myelotoxicity.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription